{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:21:12Z","timestamp":1791937272397,"version":"4.3.4"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T00:00:00Z","timestamp":1741910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Herpes zoster (HZ) is a painful vesicular rash that occurs upon varicella-zoster virus (VZV) reactivation in older adults and immunocompromised individuals. Although there is currently an approved vaccine for the prevention of shingles, its administration is commonly associated with high reactogenicity. This highlights the need to develop new vaccine alternatives with long lasting immunity and improved tolerability upon administration. In the present study, 10 different vaccine candidate designs using two different codon optimizations targeting the VZV glycoprotein E (gE) were generated. A subset of mRNA constructs were formulated into lipid nanoparticles and assessed for their ability to induce specific cellular and humoral immune responses following vaccination in mice. Notably, the selected mRNA vaccine candidates induced high levels of antibodies and robust CD4<jats:sup>+<\/jats:sup> but also CD8<jats:sup>+<\/jats:sup> immune responses. Moreover, we showed that our alternate lyophilized vaccine provides comparable immunogenicity to current liquid frozen formulations and is stable under long-term storage conditions.<\/jats:p>","DOI":"10.1038\/s41541-025-01093-1","type":"journal-article","created":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:27:54Z","timestamp":1741951674000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["A highly stable lyophilized mRNA vaccine for Herpes Zoster provides potent cellular and humoral responses"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4521-0488","authenticated-orcid":false,"given":"Raquel","family":"Munoz-Moreno","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viola","family":"Allaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eddie","family":"Gadee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Button","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan S.","family":"Maddur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyndsey","family":"Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Giannakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam Lee","family":"Campbell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Miteva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengbo","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Lotvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pirada Suphaphiphat","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0072-3463","authenticated-orcid":false,"given":"Alicia","family":"Sol\u00f3rzano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,14]]},"reference":[{"key":"1093_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1056\/NEJMcp1302674","volume":"369","author":"JI Cohen","year":"2013","unstructured":"Cohen, J. I. Clinical practice: Herpes zoster. N. Engl. J. Med. 369, 255\u2013263 (2013).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR2","doi-asserted-by":"publisher","first-page":"11425","DOI":"10.1128\/JVI.76.22.11425-11433.2002","volume":"76","author":"CC Ku","year":"2002","unstructured":"Ku, C. C., Padilla, J. A., Grose, C., Butcher, E. C. & Arvin, A. M. Tropism of varicella-zoster virus for human tonsillar CD4(+) T lymphocytes that express activation, memory, and skin homing markers. J. Virol. 76, 11425\u201311433 (2002).","journal-title":"J. Virol."},{"key":"1093_CR3","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1128\/JVI.74.4.1864-1870.2000","volume":"74","author":"W Soong","year":"2000","unstructured":"Soong, W., Schultz, J. C., Patera, A. C., Sommer, M. H. & Cohen, J. I. Infection of human T lymphocytes with varicella-zoster virus: an analysis with viral mutants and clinical isolates. J. Virol. 74, 1864\u20131870 (2000).","journal-title":"J. Virol."},{"key":"1093_CR4","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1093\/cid\/ciy953","volume":"69","author":"R Harpaz","year":"2019","unstructured":"Harpaz, R. & Leung, J. W. The Epidemiology of Herpes Zoster in the United States During the Era of Varicella and Herpes Zoster Vaccines: Changing Patterns Among Older Adults. Clin. Infect. Dis. 69, 341\u2013344 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"1093_CR5","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1386-6532(10)70002-0","volume":"48","author":"AA Gershon","year":"2010","unstructured":"Gershon, A. A. et al. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J. Clin. Virol. 48, S2\u2013S7 (2010).","journal-title":"J. Clin. Virol."},{"key":"1093_CR6","unstructured":"CDC. Clinical Overview of Shingles (Herpes Zoster), https:\/\/www.cdc.gov\/shingles\/hcp\/clinical-overview\/index.html#:~:text=Death%20rates,0.69%20per%201%20million%20population. (2024)."},{"key":"1093_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/j.pain.0000000000001718","volume":"161","author":"M Harvey","year":"2020","unstructured":"Harvey, M., Prosser, L. A., Rose, A. M., Ortega-Sanchez, I. R. & Harpaz, R. Aggregate health and economic burden of herpes zoster in the United States: illustrative example of a pain condition. Pain 161, 361\u2013368 (2020).","journal-title":"Pain"},{"key":"1093_CR8","doi-asserted-by":"publisher","unstructured":"Pan, C. X., Lee, M. S. & Nambudiri, V. E. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother 10, 25151355221084535. https:\/\/doi.org\/10.1177\/25151355221084535 (2022).","DOI":"10.1177\/25151355221084535"},{"key":"1093_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1586\/erv.11.29","volume":"10","author":"N Garcon","year":"2011","unstructured":"Garcon, N. & Van Mechelen, M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10, 471\u2013486 (2011).","journal-title":"Expert Rev. Vaccines"},{"key":"1093_CR10","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","volume":"372","author":"H Lal","year":"2015","unstructured":"Lal, H. et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N. Engl. J. Med. 372, 2087\u20132096 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR11","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1056\/NEJMoa1603800","volume":"375","author":"AL Cunningham","year":"2016","unstructured":"Cunningham, A. L. et al. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older. N. Engl. J. Med. 375, 1019\u20131032 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR12","unstructured":"CDC. Recombinant Zoster (Shingles) Vaccine: What You Need to Know. https:\/\/www.cdc.gov\/vaccines\/hcp\/current-vis\/downloads\/shingles-recombinant.pdf (2022)."},{"key":"1093_CR13","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00425-018-2911-0","volume":"248","author":"S Upadhyay","year":"2018","unstructured":"Upadhyay, S., Jeena, G. S., Shikha & Shukla, R. K. Recent advances in steroidal saponins biosynthesis and in vitro production. Planta 248, 519\u2013544 (2018).","journal-title":"Planta"},{"key":"1093_CR14","doi-asserted-by":"publisher","unstructured":"Wang, P. Natural and Synthetic Saponins as Vaccine Adjuvants. Vaccines (Basel) 9. https:\/\/doi.org\/10.3390\/vaccines9030222 (2021).","DOI":"10.3390\/vaccines9030222"},{"key":"1093_CR15","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","volume":"383","author":"FP Polack","year":"2020","unstructured":"Polack, F. P. et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603\u20132615 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1056\/NEJMoa2035389","volume":"384","author":"LR Baden","year":"2021","unstructured":"Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403\u2013416 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1093_CR17","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","volume":"38","author":"MA Monslow","year":"2020","unstructured":"Monslow, M. A. et al. Immunogenicity generated by mRNA vaccine encoding VZV gE antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates. Vaccine 38, 5793\u20135802 (2020).","journal-title":"Vaccine"},{"key":"1093_CR18","doi-asserted-by":"publisher","first-page":"12406","DOI":"10.1128\/JVI.78.22.12406-12415.2004","volume":"78","author":"J Moffat","year":"2004","unstructured":"Moffat, J. et al. Functions of the C-terminal domain of varicella-zoster virus glycoprotein E in viral replication in vitro and skin and T-cell tropism in vivo. J. Virol. 78, 12406\u201312415 (2004).","journal-title":"J. Virol."},{"key":"1093_CR19","doi-asserted-by":"publisher","unstructured":"Lin, K. et al. Comparison of the Immune Effects of an mRNA Vaccine and a Subunit Vaccine against Herpes Zoster Administered by Different Injection Methods. Vaccines (Basel) 11. https:\/\/doi.org\/10.3390\/vaccines11051003 (2023).","DOI":"10.3390\/vaccines11051003"},{"key":"1093_CR20","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2024.2309985","volume":"13","author":"L Huang","year":"2024","unstructured":"Huang, L. et al. Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques. Emerg. Microbes Infect. 13, 2309985 (2024).","journal-title":"Emerg. Microbes Infect."},{"key":"1093_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00865-5","volume":"9","author":"A Bhattacharya","year":"2024","unstructured":"Bhattacharya, A. et al. Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine. NPJ Vaccines 9, 72 (2024).","journal-title":"NPJ Vaccines"},{"key":"1093_CR22","doi-asserted-by":"publisher","first-page":"6563","DOI":"10.1128\/jvi.70.10.6563-6575.1996","volume":"70","author":"Z Zhu","year":"1996","unstructured":"Zhu, Z., Hao, Y., Gershon, M. D., Ambron, R. T. & Gershon, A. A. Targeting of glycoprotein I (gE) of varicella-zoster virus to the trans-Golgi network by an AYRV sequence and an acidic amino acid-rich patch in the cytosolic domain of the molecule. J. Virol. 70, 6563\u20136575 (1996).","journal-title":"J. Virol."},{"key":"1093_CR23","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1128\/jvi.71.5.4042-4054.1997","volume":"71","author":"JK Olson","year":"1997","unstructured":"Olson, J. K. & Grose, C. Endocytosis and recycling of varicella-zoster virus Fc receptor glycoprotein gE: internalization mediated by a YXXL motif in the cytoplasmic tail. J. Virol. 71, 4042\u20134054 (1997).","journal-title":"J. Virol."},{"key":"1093_CR24","unstructured":"Cohen, J. I., and Straus, S. E. In Fields virology Vol. 2 2707-2730 (2001)."},{"key":"1093_CR25","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1128\/jvi.67.8.4464-4473.1993","volume":"67","author":"Z Yao","year":"1993","unstructured":"Yao, Z., Jackson, W. & Grose, C. Identification of the phosphorylation sequence in the cytoplasmic tail of the varicella-zoster virus Fc receptor glycoprotein gpI. J. Virol. 67, 4464\u20134473 (1993).","journal-title":"J. Virol."},{"key":"1093_CR26","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.5858\/133.9.1463","volume":"133","author":"BP Lucey","year":"2009","unstructured":"Lucey, B. P., Nelson-Rees, W. A. & Hutchins, G. M. Henrietta Lacks, HeLa cells, and cell culture contamination. Arch. Pathol. Lab Med. 133, 1463\u20131467 (2009).","journal-title":"Arch. Pathol. Lab Med."},{"key":"1093_CR27","first-page":"341","volume":"342","author":"A Weinberg","year":"2010","unstructured":"Weinberg, A. & Levin, M. J. VZV T cell-mediated immunity. Curr. Top. Microbiol Immunol. 342, 341\u2013357 (2010).","journal-title":"Curr. Top. Microbiol Immunol."},{"key":"1093_CR28","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1080\/21645515.2016.1154247","volume":"12","author":"M Fochesato","year":"2016","unstructured":"Fochesato, M., Dendouga, N. & Boxus, M. Comparative preclinical evaluation of AS01 versus other Adjuvant Systems in a candidate herpes zoster glycoprotein E subunit vaccine. Hum. Vaccin Immunother. 12, 2092\u20132095 (2016).","journal-title":"Hum. Vaccin Immunother."},{"key":"1093_CR29","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.molmed.2013.09.002","volume":"19","author":"C Pollard","year":"2013","unstructured":"Pollard, C., De Koker, S., Saelens, X., Vanham, G. & Grooten, J. Challenges and advances towards the rational design of mRNA vaccines. Trends Mol. Med. 19, 705\u2013713 (2013).","journal-title":"Trends Mol. Med."},{"key":"1093_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1093_CR31","doi-asserted-by":"publisher","first-page":"674","DOI":"10.15585\/mmwr.mm7018e1","volume":"70","author":"MW Tenforde","year":"2021","unstructured":"Tenforde, M. W. et al. Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Among Hospitalized Adults Aged >\/=65 Years - United States, January-March 2021. MMWR Morb. Mortal. Wkly Rep. 70, 674\u2013679 (2021).","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"1093_CR32","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/infdis\/jiv164","volume":"212","author":"KJ Laing","year":"2015","unstructured":"Laing, K. J. et al. Zoster Vaccination Increases the Breadth of CD4+ T Cells Responsive to Varicella Zoster Virus. J. Infect. Dis. 212, 1022\u20131031 (2015).","journal-title":"J. Infect. Dis."},{"key":"1093_CR33","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3389\/fimmu.2015.00553","volume":"6","author":"JJ Sei","year":"2015","unstructured":"Sei, J. J. et al. Effector and Central Memory Poly-Functional CD4(+) and CD8(+) T Cells are Boosted upon ZOSTAVAX((R)) Vaccination. Front Immunol. 6, 553 (2015).","journal-title":"Front Immunol."},{"key":"1093_CR34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","volume":"217","author":"AL Cunningham","year":"2018","unstructured":"Cunningham, A. L. et al. Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older. J. Infect. Dis. 217, 1750\u20131760 (2018).","journal-title":"J. Infect. Dis."},{"key":"1093_CR35","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","volume":"20","author":"N Chaudhary","year":"2021","unstructured":"Chaudhary, N., Weissman, D. & Whitehead, K. A. mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nat. Rev. Drug Discov. 20, 817\u2013838 (2021).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1093_CR36","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1016\/j.vaccine.2012.01.088","volume":"30","author":"N Dendouga","year":"2012","unstructured":"Dendouga, N., Fochesato, M., Lockman, L., Mossman, S. & Giannini, S. L. Cell-mediated immune responses to a varicella-zoster virus glycoprotein E vaccine using both a TLR agonist and QS21 in mice. Vaccine 30, 3126\u20133135 (2012).","journal-title":"Vaccine"},{"key":"1093_CR37","doi-asserted-by":"publisher","first-page":"2704","DOI":"10.1128\/JVI.03445-13","volume":"88","author":"M Steain","year":"2014","unstructured":"Steain, M. et al. Analysis of T cell responses during active varicella-zoster virus reactivation in human ganglia. J. Virol. 88, 2704\u20132716 (2014).","journal-title":"J. Virol."},{"key":"1093_CR38","doi-asserted-by":"publisher","unstructured":"Cao, H., Wang, Y., Luan, N., Lin, K. & Liu, C. Effects of Varicella-Zoster Virus Glycoprotein E Carboxyl-Terminal Mutation on mRNA Vaccine Efficacy. Vaccines (Basel) 9. https:\/\/doi.org\/10.3390\/vaccines9121440 (2021).","DOI":"10.3390\/vaccines9121440"},{"key":"1093_CR39","doi-asserted-by":"publisher","unstructured":"Wang, Y. et al. Evaluation of the Immunological Efficacy of an LNP-mRNA Vaccine Prepared from Varicella Zoster Virus Glycoprotein gE with a Double-Mutated Carboxyl Terminus in Different Untranslated Regions in Mice. Vaccines (Basel) 11. https:\/\/doi.org\/10.3390\/vaccines11091475 (2023).","DOI":"10.3390\/vaccines11091475"},{"key":"1093_CR40","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1016\/j.ymthe.2021.05.011","volume":"29","author":"CJ Knudson","year":"2021","unstructured":"Knudson, C. J. et al. Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 T cells against a lethal viral infection. Mol. Ther. 29, 2769\u20132781 (2021).","journal-title":"Mol. Ther."},{"key":"1093_CR41","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41586-021-03653-6","volume":"595","author":"U Sahin","year":"2021","unstructured":"Sahin, U. et al. BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. Nature 595, 572\u2013577 (2021).","journal-title":"Nature"},{"key":"1093_CR42","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/jmv.1890140403","volume":"14","author":"Y Asano","year":"1984","unstructured":"Asano, Y. et al. Immunogenicity of wild and attenuated varicella-zoster virus strains in rhesus monkeys. J. Med Virol. 14, 305\u2013312 (1984).","journal-title":"J. Med Virol."},{"key":"1093_CR43","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1128\/JVI.03124-14","volume":"89","author":"C Meyer","year":"2015","unstructured":"Meyer, C. et al. Abortive intrabronchial infection of rhesus macaques with varicella-zoster virus provides partial protection against simian varicella virus challenge. J. Virol. 89, 1781\u20131793 (2015).","journal-title":"J. Virol."},{"key":"1093_CR44","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1039\/D2BM01581A","volume":"11","author":"Y Zeng","year":"2023","unstructured":"Zeng, Y., Escalona-Rayo, O., Knol, R., Kros, A. & Slutter, B. Lipid nanoparticle-based mRNA candidates elicit potent T cell responses. Biomater. Sci. 11, 964\u2013974 (2023).","journal-title":"Biomater. Sci."},{"key":"1093_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00980-3","volume":"9","author":"T Hauguel","year":"2024","unstructured":"Hauguel, T. et al. Preclinical immunogenicity and safety of hemagglutinin-encoding modRNA influenza vaccines. npj Vaccines 9, 183 (2024).","journal-title":"npj Vaccines"},{"key":"1093_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41586-021-03275-y","volume":"592","author":"AB Vogel","year":"2021","unstructured":"Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283\u2013289 (2021).","journal-title":"Nature"},{"key":"1093_CR47","doi-asserted-by":"publisher","unstructured":"Xia, X. Detailed Dissection and Critical Evaluation of the Pfizer\/BioNTech and Moderna mRNA Vaccines. Vaccines (Basel) 9. https:\/\/doi.org\/10.3390\/vaccines9070734 (2021).","DOI":"10.3390\/vaccines9070734"},{"key":"1093_CR48","doi-asserted-by":"publisher","unstructured":"Sullivan, N. L. et al. Breadth and Functionality of Varicella-Zoster Virus Glycoprotein-Specific Antibodies Identified after Zostavax Vaccination in Humans. J. Virol. 92. https:\/\/doi.org\/10.1128\/JVI.00269-18 (2018).","DOI":"10.1128\/JVI.00269-18"},{"key":"1093_CR49","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1529\/biophysj.103.038422","volume":"86","author":"SV Costes","year":"2004","unstructured":"Costes, S. V. et al. Automatic and quantitative measurement of protein-protein colocalization in live cells. Biophys. J. 86, 3993\u20134003 (2004).","journal-title":"Biophys. J."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01093-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01093-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T11:28:00Z","timestamp":1741951680000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-025-01093-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1038\/s41541-025-01093-1","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,14]]},"assertion":[{"value":"20 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was funded by Pfizer Inc. Pfizer was involved in the design, analysis, and interpretation of the data in this research study, the writing of this report, and the decision to publish. The results in this manuscript are part of a collaboration between BioNTech and Pfizer. All authors are current or former employees of Pfizer Inc., and may, consequently, be shareholders. F.D., R.M.M., A.S. and P.S.A. are listed as inventors on a patent application related to nucleoside-modified RNA LNP vaccines encoding varicella zoster virus.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"49"}}